{"id":441844,"date":"2021-02-23T08:18:15","date_gmt":"2021-02-23T13:18:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441844"},"modified":"2021-02-23T08:18:15","modified_gmt":"2021-02-23T13:18:15","slug":"chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/","title":{"rendered":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em><br \/>\n          <strong>Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials<\/strong><br \/>\n        <\/em>\n      <\/p>\n<p align=\"justify\">VANCOUVER, British Columbia and SEATTLE, Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3<sup>rd<\/sup> Annual Chronic Kidney Disease Drug Development (CKD3) Summit. Dr. King will deliver a presentation titled \u201cSelective ETA receptor antagonist atrasentan for the treatment of primary glomerular diseases\u201d on Thursday, March 4<sup>th<\/sup> at 10:00 am EST. Dr. King will also participate in a panel discussion on executing precision medicine in clinical trials on Wednesday, March 3<sup>rd<\/sup> at 2:45 pm EST.<\/p>\n<p>The 3<sup>rd<\/sup> Annual CKD3 Summit is a unique virtual conference being held March 2 \u2013 4, 2021 that will bring together key opinion leaders and stakeholders in kidney disease to identify and discuss topics pertaining to drug development from discovery through regulatory approval. For more information, please visit the CKD3 Summit website located at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hg1J8T4RF7x3gixTKYy2Aa3IcVIxlFtMtrvY37q-K0wyhgwleKmUDvELGwBP32UtWAFwmYQ8Xfclao2PTMVgdcFNktCAhdhXAFViFfkeb6g=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ckd3-summit.com\/<\/a>.<\/p>\n<p>\n        <strong>About Chinook Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook\u2019s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook\u2019s lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8Vb8BF-3ONvil49A9ke73fIRY4oBEhpwFNJO-4x3ib8Yw-AHobioqnRWOjYcxghGhdv7veCAsRoiYCY5Hq9_SA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.chinooktx.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Noopur Liffick<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ge4VT7RxMSOsnz4v1MIbFRQUl-qYOR35fv5LpPl-GS-yXRldt2ggUVxwS5_jAIpcpmg-qCpuEfVWjU2-u7oiujD6KOIYjP6TVHf6COvskRQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@chinooktx.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BioFME2qfB992I1UEWkWVvV5h171H8xqkwT9tyoZ-ufeuCTNV8BbZeR2ihK7Sph2aQZCncpQkOe-z0fhSvoZYx3QAyf5BReFgi35AkjQA60=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@chinooktx.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/49a1f553-e517-4b85-aa86-0644e1bfc727\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials VANCOUVER, British Columbia and SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit. Dr. King will deliver a presentation titled \u201cSelective ETA receptor antagonist atrasentan for the treatment of primary glomerular diseases\u201d on Thursday, March 4th at 10:00 am EST. Dr. King &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441844","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials VANCOUVER, British Columbia and SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit. Dr. King will deliver a presentation titled \u201cSelective ETA receptor antagonist atrasentan for the treatment of primary glomerular diseases\u201d on Thursday, March 4th at 10:00 am EST. Dr. King &hellip; Continue reading &quot;Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T13:18:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit\",\"datePublished\":\"2021-02-23T13:18:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/\",\"name\":\"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\",\"datePublished\":\"2021-02-23T13:18:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/","og_locale":"en_US","og_type":"article","og_title":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk","og_description":"Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials VANCOUVER, British Columbia and SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit. Dr. King will deliver a presentation titled \u201cSelective ETA receptor antagonist atrasentan for the treatment of primary glomerular diseases\u201d on Thursday, March 4th at 10:00 am EST. Dr. King &hellip; Continue reading \"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T13:18:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit","datePublished":"2021-02-23T13:18:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/","name":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=","datePublished":"2021-02-23T13:18:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzczMyMzOTg5NzQyIzIwMTExODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chinook-therapeutics-to-present-at-3rd-annual-chronic-kidney-disease-drug-development-ckd3-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441844"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}